Longeveron Inc (LGVN) fair value: what the stock is really worth
As of Oct 16, 2026: fair value (intrinsic value) of Longeveron Inc stock $0.28, price $1.39, upside -79.9%, quality 32 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range $1.39 – $4,230 · fair‑value band $0.1900 – $0.3600 · the $1.39 price screens above the $0.2800 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Longeveron in your weekly email
Every Wednesday you see whether Longeveron is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
Show moreShow less
Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
The company was incorporated in 2014 and is headquartered in Miami, Florida.
Stock analysis
Longeveron Inc (LGVN) currently trades at $1.39, while our model-based Fair Value estimate is $0.2800, 79.9% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.1900 (bear) to $0.3600 (bull), the price of $1.39 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Longeveron Inc reported revenue of $1.2M in FY2025 versus $1.3M in FY2021, a compound −2.1%/yr. Reported net income was −$22.7M in FY2025.
Key figures
Market cap $8.2M · P/S ratio 6.93 · EPS (TTM) $−10.00 · Return on equity −204% · Return on assets (EBIT) −114% · Operating margin −2,150% · Revenue (TTM) $1.2M · Revenue growth (YoY) −9.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 88% below its 52-week high and at its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −80%, LGVN screens richer than that median.
Fair Value models
Bear$0.1900Fair Value $0.2800Bull$0.3600
Price $1.39 · Upside -79.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−49.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−26.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.9%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−67.1% (2020) → −1,942.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 602 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−79.9% · Bottom 25%
Growth and dividend
Revenue growth−9.2% · Below median
Balance sheet
Debt / equity0.36× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.45× · Cheaper than median
P/S (12 months)6.93× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)82· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Longeveron Inc Fair Value". https://www.fairvalue-calculator.com/stock/LGVN
Frequently asked questions
Is Longeveron Inc (LGVN) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of $0.2800 versus a price of $1.39, about −80% upside (overvalued).
What is the fair value of LGVN?
Our model-based fair value for Longeveron Inc is $0.2800 (as of Oct 4, 2026), built from audited fundamentals. The current price: $1.39.
What is the quality score of LGVN?
Longeveron Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Longeveron Inc (LGVN)?
Our model-based price target is the fair value of $0.2800 (as of Oct 4, 2026) from 1 valuation models. Cautious scenario $0.1900, optimistic scenario $0.3600. It is a calculation from audited fundamentals, not an analyst target.
What is the Longeveron Inc stock forecast for 2026?
Our models put fair value at $0.2800, about −80% upside versus a price of $1.39 (overvalued). Cautious scenario $0.1900, optimistic scenario $0.3600. The calculation is refreshed regularly with new filings.
What is the revenue of Longeveron Inc (LGVN)?
Longeveron Inc reported trailing-twelve-month revenue of about $1.2M (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Longeveron Inc (LGVN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Longeveron Inc it is $0.2800 per share (as of Oct 4, 2026), against a price of $1.39. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Longeveron Inc stock overvalued or undervalued in 2026?
As of Oct 4, 2026, LGVN trades above its calculated fair value: price $1.39, fair value $0.2800, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LGVN?
No. The price is what the market pays today ($1.39); the fair value is what the company's own numbers justify ($0.2800). For Longeveron Inc the two are $1.11 per share apart. That gap is exactly why we show both numbers side by side.
How much is Longeveron Inc worth?
The market values Longeveron Inc at about $8.2M (market capitalisation, as of Oct 4, 2026). Per share that is $1.39; our models calculate a fair value of $0.2800 per share.
What do the bullish and bearish scenarios say about LGVN?
Our models span a range for Longeveron Inc: cautious scenario $0.1900, base $0.2800, optimistic $0.3600 per share (as of Oct 4, 2026, price $1.39). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Longeveron Inc (LGVN)?
Balance-sheet figures for Longeveron Inc (as of Oct 4, 2026): return on equity −203.6%, debt of 0.36 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is LGVN from its 52-week high?
Longeveron Inc trades at $1.39, about 88% below its 52-week high of $11.60 and at the low of $1.39 (as of Oct 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2800 is for.
Which stocks are comparable to Longeveron Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Longeveron Inc stock attractive at the current price?
The data as of Oct 4, 2026: price $1.39, calculated fair value $0.2800 (−80%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LGVN calculated?
We run Longeveron Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.2800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7 % above its aggregate fair value. Longeveron Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Longeveron Inc (LGVN)?
The closing price on Oct 16, 2026 was $1.39. Our model-based fair value is $0.2800, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Longeveron Inc right now?
The price sits above even our optimistic bull case ($0.3600). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1900 to $0.3600) leaves room in how you read the outcome.
Key figures of Longeveron Inc
How large is the market capitalisation of Longeveron Inc (LGVN)?
The market capitalisation of Longeveron Inc is $8.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Longeveron Inc (LGVN)?
The price-to-sales ratio of Longeveron Inc is 6.93 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Longeveron Inc (LGVN)?
Earnings per share at Longeveron Inc are $−10.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Longeveron Inc (LGVN)?
The return on equity (ROE) of Longeveron Inc is −204% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Longeveron Inc (LGVN)?
On an EBIT basis the return on assets of Longeveron Inc is −114% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Longeveron Inc (LGVN)?
The operating margin of Longeveron Inc is −2,150% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Longeveron Inc (LGVN)?
Revenue at Longeveron Inc is growing −9.2% versus a year earlier (3y avg −0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Longeveron Inc (LGVN) generate?
The free cash flow of Longeveron Inc is −$18.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Longeveron Inc (LGVN) hold?
Longeveron Inc holds more cash than debt, $3.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Longeveron Inc in the live analysis
One click puts Longeveron Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 4, 2026